Is Savolitinib Effective for Lung Cancer?

From March 30 to April 2, 2022, Alfredo Addeo and colleagues from Geneva University Hospital presented the results of a Phase 2 clinical trial of the oral MET inhibitor Savolitinib in patients with MET exon 14 skipping mutation-positive non-small cell lung cancer (NSCLC) at the European Lung Cancer Congress (ELCC) in Prague, Czech Republic.

This Phase 2 trial evaluated the efficacy and safety of Savolitinib in 70 patients with MET exon 14 skipping mutation-positive NSCLC. The primary endpoint was overall survival (OS).

Of the 70 participants, 42 had prior treatment and 28 were treatment-naive. Histological types included 25 patients with pulmonary sarcomatoid carcinoma (PSC) and 45 with other NSCLC subtypes. The results were as follows:

With a median follow-up of 28.4 months, the median OS for all patients was 12.5 months. The 18-month OS rate was 42%, and the 24-month OS rate was 31%.

For PSC patients, the median OS was 10.6 months, with an 18-month OS rate of 30% and a 24-month OS rate of 26%.

For patients with other NSCLC subtypes, the median OS was 17.3 months, with an 18-month OS rate of 49% and a 24-month OS rate of 34.7%.

Regarding safety, the incidence of Grade 3 or higher adverse events was 46%. The most common Grade 3 or higher adverse events were AST elevation (13%), ALT elevation (10%), and peripheral edema (9%).

Based on these Phase 2 results, Alfredo Addeo stated that MET exon 14 skipping mutations occur in approximately 3-5% of NSCLC patients and serve as a clinically meaningful driver mutation for targeted therapy. Furthermore, given the poor prognosis of PSC, Savolitinib shows promising utility for this patient population.

Source: https://dailyreporter.esmo.org/european-lung-cancer-congress-2022/congress-highlights/encouraging-results-with-savolitinib-in-nsclc-with-met-exon14-skipping-mutations

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Lung cancer